ViaCyte's implantable cell-based therapy for type 1 diabetes THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Taking even the most promising therapy and moving it out of the lab and into people is an incredibly complex process and usually requires a great team. Now, two great teams have paired up to do just that … Continue reading Type 1 diabetes therapy gets go-ahead for clinical trial
CRISPR Therapeutics
New partnership to make CIRM supported treatment for type 1 diabetes even better
ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better
The Stem Cellar 